Toreforant

Toreforant is a drug that was under development for the treatment of rheumatoid arthritis and inflammatory bowel disease. It acts as a selective antagonist for the Histamine H4 receptor, which is a protein that is part of the class A family of G protein-coupled receptors.

History[edit | edit source]

Toreforant was developed by Pfizer, a multinational pharmaceutical corporation. The drug was in Phase II clinical trials for the treatment of rheumatoid arthritis and inflammatory bowel disease. However, the development was discontinued due to lack of efficacy.

Mechanism of Action[edit | edit source]

Toreforant acts as a selective antagonist for the Histamine H4 receptor. This receptor is involved in the regulation of inflammatory responses in the body. By blocking this receptor, Toreforant can potentially reduce inflammation and alleviate symptoms of diseases such as rheumatoid arthritis and inflammatory bowel disease.

Clinical Trials[edit | edit source]

Toreforant underwent Phase II clinical trials for the treatment of rheumatoid arthritis and inflammatory bowel disease. However, the trials did not show sufficient efficacy of the drug, leading to the discontinuation of its development.

See Also[edit | edit source]

Toreforant Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.